Incyte Corporation
INCYLast close · Oct 16, 2026113.07−0.20 (−0.18%)
Market cap$22.9B
15 firms' latest targets, last 90 days: median $130.00 ($104.00–$157.00), 15% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-16 | Raymond James | $152.00 | — | +34% |
| 2026-10-14 | Truist | $115.00 | ▲ 10% | +2% |
| 2026-10-08 | RBC Capital | $114.00 | ▲ 5% | +1% |
| 2026-10-05 | UBS | $127.00 | ▲ 12% | +12% |
| 2026-10-05 | Stifel | $157.00 | ▲ 8% | +39% |
| 2026-09-28 | H.C. Wainwright | $152.00 | ▲ 1% | +34% |
| 2026-08-20 | Canaccord Genuity | $152.00 | — | +34% |
| 2026-08-17 | Piper Sandler | $130.00 | ▲ 18% | +15% |
| 2026-08-13 | Bernstein | $104.00 | ▲ 5% | -8% |
| 2026-08-03 | Leerink Partners | $155.00 | — | +37% |
| 2026-07-29 | BMO Capital | $130.00 | ▲ 16% | +15% |
| 2026-07-29 | Guggenheim | $150.00 | — | +33% |
| 2026-07-29 | Morgan Stanley | $119.00 | ▲ 14% | +5% |
| 2026-07-29 | Barclays | $139.00 | ▲ 4% | +23% |
| 2026-07-28 | Oppenheimer | $120.00 | ▲ 12% | +6% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $3.7B | +9% | $2.65 | +74% | est. $3.7B+0% | est. $3.60 | 12 |
| 2024reported | $4.2B | +15% | $0.15 | -94% | est. $4.2B+1% | est. $1.28 | 16 |
| 2025reported | $5.1B | +21% | $6.41 | +4173% | est. $5.0B+3% | est. $6.76 | 16 |
| 2026 | $5.9B | +15% | $3.28 | -52% | $5.9B–$6.0B | $2.59–$3.91 | 18 |
| 2027 | $6.2B | +5% | $8.17 | +149% | $6.0B–$6.7B | $7.24–$9.15 | 18 |
| 2028 | $6.5B | +5% | $8.94 | +9% | $5.4B–$7.7B | $6.62–$11.73 | 18 |
| 2029 | $5.0B | -23% | $3.33 | -63% | $4.8B–$5.4B | $3.13–$3.63 | 10 |
| 2030 | $5.5B | +9% | $4.44 | +33% | $5.2B–$5.9B | $4.17–$4.84 | 9 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.